David Arkowitz Net Worth

The estimated Net Worth of David Arkowitz is at least $5.3 million dollars as of 14 February 2024. Mr. Arkowitz owns over 10,625 units of Flexion Therapeutics Inc stock worth over $1,712,841 and over the last 18 years he sold FLXN stock worth over $372,361. In addition, he makes $3,212,900 as Chief Financial Officer at Flexion Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Arkowitz FLXN stock SEC Form 4 insiders trading

David has made over 20 trades of the Flexion Therapeutics Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 10,625 units of FLXN stock worth $97,644 on 14 February 2024.

The largest trade he's ever made was exercising 13,209 units of Flexion Therapeutics Inc stock on 27 October 2023 worth over $121,391. On average, David trades about 1,265 units every 99 days since 2007. As of 14 February 2024 he still owns at least 186,381 units of Flexion Therapeutics Inc stock.

You can see the complete history of Mr. Arkowitz stock trades at the bottom of the page.

David Arkowitz biography

David A. Arkowitz serves as Chief Financial Officer of the Company. Mr. Arkowitz joined the Company as Chief Financial Officer in 2018. Prior to joining the Company, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc., where he led the finance, business development, corporate planning, and other functions. Since 2014, Mr. Arkowitz has also served on the board of directors and as chair of the audit committee of Spring Bank Pharmaceuticals, Inc., a public biopharmaceutical company, and he was appointed to the board of directors of Proteostatis Therapeutics in March of 2019. Previously Mr. Arkowitz was CFO at Mascoma Corporation, AMAG Pharmaceuticals and Idenix Pharmaceuticals and held additional leadership positions within each company. Preceding his tenure at Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. operations, Controller of the global research and development division, and CFO of the Canadian subsidiary. He obtained his BA in mathematics at Brandeis University and his MBA in finance at Columbia University Business School.

What is the salary of David Arkowitz?

As the Chief Financial Officer of Flexion Therapeutics Inc, the total compensation of David Arkowitz at Flexion Therapeutics Inc is $3,212,900. There are 1 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.

How old is David Arkowitz?

David Arkowitz is 58, he's been the Chief Financial Officer of Flexion Therapeutics Inc since 2018. There are 8 older and 8 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.

What's David Arkowitz's mailing address?

David's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon et Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.

What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.

Complete history of Mr. Arkowitz stock trades at AMAG Pharmaceuticals, Flexion Therapeutics Inc, Proteostasis Therapeutics Inc, Seres Therapeutics Inc et Spring Bank Pharmaceuticals

Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Clayman,
  President, Chief Executive Officer, Director
• David Arkowitz,
  Chief Financial Officer
• Scott Kelley,
  Chief Medical Officer
• Mark Levine,
  General Counsel and Corporate Secretary
• Dr. Neil Bodick,
  Consultant
• Patrick Mahaffy,
  Independent Chairman of the Board
• Sandesh Mahatme,
  Independent Director
• Samuel Colella,
  Independent Director
• Alan Milinazzo,
  Independent Director
• Mark Stejbach,
  Independent Director
• C. Ann Merrifield,
  Independent Director
• Scott Canute,
  Independent Director
• Heath Lukatch,
  Independent Director
• Scott Young,
  IR Contact Officer
• Elizabeth Kwo,
  Director
• Christina Willwerth,
  Chief Strategy Officer
• Kerry Wentworth,
  Chief Regulatory Officer
• Melissa Layman,
  Chief Commercial Officer
• John Magee,
  VP of Sales
• Carolyn Beaty Scimemi,
  VP, Legal Affairs & Chief Compliance Officer
• David A. Arkowitz M.B.A.,
  Chief Financial Officer
• Ventures Iii, Llc Versant V...,
  
• Yamo Deniz,
  Chief Medical Officer
• Frederick W Driscoll,
  Chief Financial Officer
• Barbara N Bolzon Bradley J ...,
  
• William T. Andrews,
  Chief Medical Officer
• Utpal Koppikar,
  Director
• Neil Bodick,
  Chief Scientific Officer
• Ventures Ii Lp5 Am Co Inves...,
  
• Holdings A/S Novo,
  10% owner
• Partners Sas Sofinnova,
  10% owner
• Venture Capital Iii, L.P.Bo...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Rafael Tordjman,
  Director
• Andrew J. Schwab,
  Director
• Bradley J Ph D Bolzon,
  Director
• Venture Capital Iii, L.P.Ve...,
  
• Inc Pfizer,
  10% owner
• Management, Llc Newtyn,
  10% owner
• Adam Muzikant,
  Chief Business Officer